Search Results
Results found for "Shane Wright"
- Breaking the Myth of High and Low Affinity Sites
Yet some assumptions still shaping pharmacology workflows haven’t evolved as fast as today’s science. The analytical tools that shaped traditional affinity analysis were designed for simpler systems.
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
This simple advice, passed on to Ben in grad school, has helped him stay sane, focused, and impactful Imposter Syndrome and Finding Your Place Ben shares the moment he realized he mattered, when he was
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
endocrine-related tumors, announced today the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Randy Hall's study: GPR37L1's role in shaping cortical astrocytes during development Dr. Want to share your project informally? Submit a 1-minute abstract video using this form.
- Integrated GPCR Drug Discovery: A Structured Framework for Modern Programs
Platform selection shapes interpretation. Infrastructure influences velocity. DrGPCR Podcast, Keyvan Sedaghat joins the conversation to explore how membrane compartmentalization shapes
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
The natural ligand of the target receptor provides an excellent scaffold, already with a size and shape Right: Orion ligand analogs are engineered to optimize transmembrane domain providing significantly increased Orion’s PROcisionXᵀᴹ Platform In Orion’s discovery process, shape space at the TM domain ‘message’ site Since shape space exploration is specifically focused on the ‘message’ site in the TM domain, this means
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Terry Kenakin Monthly Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape Scientists acting on today’s insight will shape tomorrow’s breakthroughs. 40 years of expertise at your
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
. ✅ Practical insight into how enzyme activation and inhibition shape drug safety, efficacy, and design a molecule directly blocks the substrate’s access) from allosteric inhibition, which alters enzyme shape toughest pharmacology questions — from receptor bias and assay design to enzyme kinetics — and help shape
- Sign Up Now!
GPCR Summit from October 10th to the 16th is taking shape.
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
So I designed my own PhD program,” Sokhom shared.
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
realization was that these small, single-transmembrane proteins weren’t just chaperones; they actively shaped
- New Podcast, Sweet Structures & $2.2B GPCR Moves
A new commentary highlights how detergents and cholesterol shape mGluR2 activation—no ligand required
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
. 🔍 Quick Wins This Week 🔹 Tell us what matters → News Survey Your 1-minute feedback shapes what
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
In this episode, Catherine reflects on how her identity as a scientist took shape, why she’s committed That kind of street-level data shapes everything: dosing strategies that reflect actual potencies in
- When Pain Becomes a Catalyst: How Personal Experience Redefined One Scientist’s Mission
This is a story about how chronic pain doesn't just shape lives — it reshapes careers.
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
Instead, it aims for useful, testable predictions that shape the next experiment. Learn from the field’s top innovators. 📈 Sharpen your translational impact. 🔗 Connect with scientists shaping
- The Five Traps of Ignoring Kinetics
Methods to detect hidden mechanisms—mixtures, dual effects, or time-dependent inhibition—through curve shapes Use curve shapes as diagnostics: flattened, biphasic, or lagging responses aren’t noise.
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery
- Mapping Motion: Intermediate States, Deorphanization & Discovery
GPCR Symposia and dive into big ideas from top scientists, early-career researchers, and innovators shaping
- Production of human A2AAR in lipid nanodiscs for 19F-NMR and single-molecule fluorescence...
We explain in detail steps shared between the two sample preparation strategies, including expression
- Production of human A2AAR in lipid nanodiscs for 19F-NMR and single-molecule fluorescence...
We explain in detail steps shared between the two sample preparation strategies, including expression
- Structural dynamics of Smoothened (SMO) in ciliary membrane and its interaction with membrane lipids
in the ciliary membrane, and to gain molecular-level insights into the role of the primary cilia in shaping reveals the movements of TM5, TM6, and TM7, linked with the helix8, which are possibly involved in shaping
- Dr. Nicola J. Smith - Dr. GPCR Podcast
Please share! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast
- 📰 GPCR Weekly News, April 1 to 7, 2024
We're excited to share our coverage of the latest developments in GPCRs for this week. We also ask that you share this with your eligible colleagues.
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies
- 📰 GPCR Weekly News - January 2 to 8, 2023
Hello Readers👋, We're excited to share our weekly newsletter with you. Sherwin Sells 30,000 Shares STALICLA signs agreement with Novartis on neurodevelopmental disorders Call
- Dr. GPCR and Eurofins DiscoverX Join Forces to Accelerate GPCR Drug Discovery
“Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
Our conversation provided additional insight you cannot find in a job description, so I thought I’d share




















